Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc Common Stock (ABBV) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 99,586,072
  • Shares Outstanding, K 1,628,540
  • Annual Sales, $ 22,859 M
  • Annual Income, $ 5,144 M
  • 36-Month Beta 1.58
  • Price/Sales 3.95
  • Price/Book 15.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.42 +2.60%
on 01/12/17
64.50 -3.89%
on 01/10/17
unch (unch)
since 12/13/16
3-Month
55.06 +12.59%
on 10/28/16
65.05 -4.70%
on 11/10/16
+0.84 (+1.37%)
since 10/13/16
52-Week
50.71 +22.24%
on 01/14/16
68.12 -9.00%
on 08/15/16
+10.81 (+21.12%)
since 01/13/16

Most Recent Stories

More News
Coherus Offers Positive Phase III Data on Humira Biosimilar

Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the...

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.

AbbVie's HCV Combo Favorable in Japanese Phase III Study

AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.

AbbVie, Genomics Medicine Ireland and WuXi NextCODE Announce Landmark Population Genomics Alliance

Effort will sequence the genomes of 45,000 participants from across Ireland to identify novel targets and advance the clinical development of better treatments for a range of serious diseases

AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced four new collaborations and investments with leading healthcare innovators to advance early-stage research in key therapeutic areas...

Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira....

Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment...

Blog Coverage J&J Bailed Out from $1 Billion Lawsuits, Settled the Claim for About $500 Million

Upcoming AWS Coverage on AbbVie

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Support & Resistance

2nd Resistance Point 63.18
1st Resistance Point 62.58
Last Price 61.99
1st Support Level 61.22
2nd Support Level 60.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.